Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
about
Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian IndiansMitogen-activated protein kinase regulates transcription of the ApoCIII gene. Involvement of the orphan nuclear receptor HNF4Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalphaEffects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic miceLysophosphatidylcholine acyltransferase 3 knockdown-mediated liver lysophosphatidylcholine accumulation promotes very low density lipoprotein production by enhancing microsomal triglyceride transfer protein expressionAn apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphismsCommon variants at 30 loci contribute to polygenic dyslipidemiaMetabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteinsAssociations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.Apolipoprotein A-V gene therapy for disease prevention / treatment:a critical analysisThe crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemiaIncreased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liverExpression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditionsFunctional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemiaGenomic interval engineering of mice identifies a novel modulator of triglyceride productionMice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasisApoprotein C-III deficiency markedly stimulates triglyceride secretion in vivo: comparison with apoprotein EIncreased response to cholesterol feeding in apolipoprotein C1-deficient miceA potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle.Stimulation of the in vivo production of very low density lipoproteins by apolipoprotein E is independent of the presence of the low density lipoprotein receptor.Peroxisome proliferator-activated receptor-gamma regulates the expression and function of very-low-density lipoprotein receptor.Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic miceLiver proteomic response to hypertriglyceridemia in human-apolipoprotein C-III transgenic mice at cellular and mitochondrial compartment levelsOrphan nuclear hormone receptor Rev-erbalpha regulates the human apolipoprotein CIII promoter.Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice.Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption or feeding behavior.Complexities of plasma apolipoprotein C-III metabolismFibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibratesTherapeutic considerations for postprandial dyslipidaemia.GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden micePlasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.Apolipoprotein c3 gene polymorphisms are not a risk factor for developing non-alcoholic Fatty liver disease: a meta-analysisAcute central neuropeptide Y administration increases food intake but does not affect hepatic very low-density lipoprotein (VLDL) production in miceDissociation between APOC3 variants, hepatic triglyceride content and insulin resistance.Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy.Evolving targets for lipid-modifying therapyCETP expression reverses the reconstituted HDL-induced increase in VLDL.Maternal inheritance of severe hypertriglyceridemia impairs glucose metabolism in offspring.Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance
P2860
Q21283798-CAF8BE27-E11B-4245-84FC-0BD1DE7F8793Q22010768-2AAF320E-F2F0-4B0F-9668-14B15B08DAD6Q24290442-1ED356E7-65B9-4D4F-AEBB-61016BE4B5BCQ24302828-0264C672-F227-4AB8-8B6F-41651924B86DQ24314933-0FB4549F-1E1C-4095-8D55-A2E6CC7F7BD6Q24562942-02C2D665-22D3-4B52-B5ED-47033F8BB6F7Q24598765-B45EAB5B-18EB-4AD8-9744-67DDF6A5F492Q24651503-99705F6B-2E7D-4273-96FD-13385DF98075Q25255216-6BCA6080-36D6-4C97-B6DC-96317AECC917Q26775009-B69A4AB1-C8C0-40AB-A537-D10184AD485DQ26864682-DD9900ED-36A0-4733-BADB-85D7B6A731D5Q28243492-0AC916CF-6CC0-41C5-8633-0D691BF56221Q28252652-79AD1D6C-1B11-4122-88FC-BD0B2BD2941DQ28271254-BE3326E6-247E-4BBA-AAAC-778B870AE709Q28504607-F9139F07-3AFD-414C-A660-DFB896BFB1BAQ28504875-D7D1F0FF-50B3-43CA-8E19-D2C074C1C64FQ28508473-9BCDC1E1-969B-45A0-B463-5299A9540BC8Q28587768-A7CBC31E-10AF-4C7B-8F06-1866395F8731Q31833512-C2631C80-F1B2-498C-8E34-E905B6E2C9AFQ33182404-A4413BAB-E26C-41AE-A743-5F4891325135Q33589043-04A56CB3-5625-4FF6-B77D-6E2B9610B1A5Q33727061-39451D82-FC2E-4BBF-B720-6BCC88FE6622Q33900976-E625C5D8-6AD6-44BA-A02C-20C6318CE128Q33958622-3E47D065-F369-45D7-B041-34446CFEA604Q34129395-B33BC921-4B62-4405-9729-1E346DA124DCQ34140679-BE9EC377-B24D-4AC8-B553-B220F388FC1BQ34141163-C07D0DCC-C6BB-40B1-BF8B-FCB095B6F39BQ34172178-5308CD1D-340B-40EC-9E6B-A7B3344D1E49Q34201490-90F58751-B78A-4235-9BC6-F7D65F715E17Q34285956-079343C9-2308-45DD-A7EA-18973256880AQ34469947-9B29A01F-2B59-464A-BAEB-921D9881D9F5Q34480492-288A4923-AFF0-4E37-B568-395BA0FE20D9Q34606616-A603CEC7-9F22-423D-979A-06AFA49D5E56Q34608233-D7D40EA1-0BCA-4EF1-A8A2-F0B07EDE1E44Q34674263-1F40197B-1890-4713-B260-1AA2B5AEC42DQ34829428-FF69252E-711C-4DEC-886C-9A28B1AF1FC7Q34880292-8A8EA333-1952-4AA8-B241-4C3EB718C193Q35107299-5BADD32A-9C0B-4315-9688-0B67D2394293Q35310272-6EB1ECB9-D294-4ADD-91A1-097D1D5FCC87Q35489364-96DC2D7A-B9D6-4A18-826D-F2890EF27795
P2860
Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Mechanism of hypertriglyceride ...... educed apo E on the particles.
@ast
Mechanism of hypertriglyceride ...... educed apo E on the particles.
@en
type
label
Mechanism of hypertriglyceride ...... educed apo E on the particles.
@ast
Mechanism of hypertriglyceride ...... educed apo E on the particles.
@en
prefLabel
Mechanism of hypertriglyceride ...... educed apo E on the particles.
@ast
Mechanism of hypertriglyceride ...... educed apo E on the particles.
@en
P2093
P2860
P356
P1476
Mechanism of hypertriglyceride ...... educed apo E on the particles.
@en
P2093
E A Fisher
H N Ginsberg
J L Breslow
K Aalto-Setälä
R Ramakrishnan
T Chajek-Shaul
P2860
P304
P356
10.1172/JCI116066
P407
P577
1992-11-01T00:00:00Z